The new systems allow IsoPlexis to make its functional proteomics accessible to any labs, it said. IsoSpark features an 18-inch footprint and four-chip capacity, while IsoSpark Duo features an eight-chip capacity, according to the firm. The technologies provide end-to-end automation and highly multiplexed proteomics capabilities with increased scalability. The systems are fully compatible with IsoPlexis' full suite of applications and can be used for a number of applications including cancer immunology, infectious disease, cell therapy, targeted therapies, and inflammation.

IsoPlexis plans to begin shipping IsoSpark and IsoSpark Duo in January 2021.

IsoPlexis launches new COVID-19 proteomics grant challenge
IsoPlexis has unveiled its Single-Cell Proteomics COVID-19 Grant Challenge, which will award 12 of the company's IsoCode or CodePlex chips to two winners...

IsoPlexis, Lonza partner on cell therapy manufacturing
IsoPlexis and Lonza have partnered to advance automated cell therapy manufacturing.

IsoPlexis partners with Columbia for vaccine development
IsoPlexis is partnering with Columbia University's Division of Infectious Diseases to create a vaccine for COVID-19. IsoPlexis' Single-Cell Secretome...